biostudies-literatureLuque AENCATS NIH HHSNCRR NIH HHSNIAID NIH HHS2094-101https://www.ebi.ac.uk/biostudies/studies/S-EPMC4356823biostudies-literatureUnknown59(4)We conducted an open-label, steady-state pharmacokinetic (PK) study of drug-drug interactions between depot medroxyprogesterone acetate (DMPA) and twice-daily lopinavir (LPV) plus low-dose ritonavir (RTV) (LPV/r) among 24 HIV-infected women and compared the results to those for HIV-infected women receiving DMPA while on no antiretroviral therapy or on nucleosides only (n = 14 subjects from the control arm of AIDS Clinical Trials Group [ACTG] study 5093). The objectives of the study were to address the effect of LPV/r on DMPA and to address the effect of DMPA on LPV/r therapy. PK parameters were estimated using noncompartmental analysis with between-group comparisons of medroxyprogesterone acetate (MPA) PKs and within-subject comparisons of LPV and RTV PKs before and 4 weeks after DMPA dosiAntimicrobial agents and chemotherapyDepot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.PMC4356823UM1 AI069423P30 AI050410AI068634UL1 TR000150UM1 AI068632UM1AI068616UM1 AI106716U01 AI069481UM1 AI068634UM1AI068636UM1 AI068636UM1AI1067161U01AI068636UM1 AI068616UM1AI068632UL1TR000150U01 AI068636UL-1RR02460UM1 AI0694811U01AI069481UM1 AI106701UM1 AI069511P30 AI50410U01 AI069471UL1 TR002489P30 AI027763UL1 TR0011111U01AI0695131U01AI0695111U01AI0694711UL1TR001111UM1 AI069471UM1-AI069423-08UM1 AI069496U01 AI069511U01 AI069513Weinberg AKlingman KLPark JGLivingston ECohn SEWatts DHLuque AECramer YAweeka FfalseDepot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the ACTG 5283 study.We conducted an open-label, steady-state pharmacokinetic (PK) study of drug-drug interactions between depot medroxyprogesterone acetate (DMPA) and twice-daily lopinavir (LPV) plus low-dose ritonavir (RTV) (LPV/r) among 24 HIV-infected women and compared the results to those for HIV-infected women receiving DMPA while on no antiretroviral therapy or on nucleosides only (n = 14 subjects from the control arm of AIDS Clinical Trials Group [ACTG] study 5093). The objectives of the study were to address the effect of LPV/r on DMPA and to address the effect of DMPA on LPV/r therapy. PK parameters were estimated using noncompartmental analysis with between-group comparisons of medroxyprogesterone acetate (MPA) PKs and within-subject comparisons of LPV and RTV PKs before and 4 weeks after DMPA dosi2015-01-01T00:00:00Z2015 Apr2025-04-04T19:19:57.216Z2019-03-27T01:48:02ZS-EPMC43568232562432610.1128/AAC.04701-1410.1128/aac.04701-14